The IgA Nephropathy (Berger’s Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for IgA Nephropathy (Berger’s Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for IgA Nephropathy (Berger’s Disease) and features dormant and discontinued products.
GlobalData tracks 63 drugs in development for IgA Nephropathy (Berger’s Disease) by 50 companies/universities/institutes. The top development phase for IgA Nephropathy (Berger’s Disease) is preclinical with 19 drugs in that stage. The IgA Nephropathy (Berger’s Disease) pipeline has 60 drugs in development by companies and three by universities/ institutes. Some of the companies in the IgA Nephropathy (Berger’s Disease) pipeline products market are: Jiangsu Hengrui Medicine, Transcenta and Novartis.
The key targets in the IgA Nephropathy (Berger’s Disease) pipeline products market include Complement Factor B, Mannan Binding Lectin Serine Protease 2, and Tumor Necrosis Factor Ligand Superfamily Member 13.
The key mechanisms of action in the IgA Nephropathy (Berger’s Disease) pipeline product include Mannan Binding Lectin Serine Protease 2 Inhibitor with eight drugs in Phase II. The IgA Nephropathy (Berger’s Disease) pipeline products include seven routes of administration with the top ROA being Subcutaneous and 12 key molecule types in the IgA Nephropathy (Berger’s Disease) pipeline products market including Monoclonal Antibody, and Small Molecule.
IgA Nephropathy (Berger’s Disease) overview
IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy is not fully understood, but it is believed to involve an abnormal immune system response, where the body produces IgA antibodies that are not effectively cleared from the bloodstream and deposit in the kidneys. Genetic and environmental factors may also contribute to its development. IgA nephropathy may initially present without noticeable symptoms, but as the disease progresses, individuals may experience blood in the urine (hematuria), which may be visible or detected through urine tests; proteinuria, or the presence of excess protein in the urine; high blood pressure; and swelling in the hands, feet, face, or abdomen due to fluid retention (edema).
For a complete picture of IgA Nephropathy (Berger’s Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
